Literature DB >> 25926444

Orexin-corticotropin-releasing factor receptor heteromers in the ventral tegmental area as targets for cocaine.

Gemma Navarro1, César Quiroz2, David Moreno-Delgado1, Adam Sierakowiak2, Kimberly McDowell2, Estefanía Moreno1, William Rea2, Ning-Sheng Cai2, David Aguinaga1, Lesley A Howell3, Felix Hausch4, Antonio Cortés1, Josefa Mallol1, Vicent Casadó1, Carme Lluís1, Enric I Canela1, Sergi Ferré5, Peter J McCormick6.   

Abstract

Release of the neuropeptides corticotropin-releasing factor (CRF) and orexin-A in the ventral tegmental area (VTA) play an important role in stress-induced cocaine-seeking behavior. We provide evidence for pharmacologically significant interactions between CRF and orexin-A that depend on oligomerization of CRF1 receptor (CRF1R) and orexin OX1 receptors (OX1R). CRF1R-OX1R heteromers are the conduits of a negative crosstalk between orexin-A and CRF as demonstrated in transfected cells and rat VTA, in which they significantly modulate dendritic dopamine release. The cocaine target σ1 receptor (σ1R) also associates with the CRF1R-OX1R heteromer. Cocaine binding to the σ1R-CRF1R-OX1R complex promotes a long-term disruption of the orexin-A-CRF negative crosstalk. Through this mechanism, cocaine sensitizes VTA cells to the excitatory effects of both CRF and orexin-A, thus providing a mechanism by which stress induces cocaine seeking.
Copyright © 2015 the authors 0270-6474/15/356639-15$15.00/0.

Entities:  

Keywords:  CRF receptor; GPCR heteromer; cocaine; orexin receptor; sigma receptor

Mesh：

Substances：

Year:  2015        PMID： 25926444      PMCID： PMC4412889          DOI： 10.1523/JNEUROSCI.4364-14.2015

Source DB:  PubMed          Journal:  J Neurosci        ISSN： 0270-6474            Impact factor:   6.167


  43 in total

Review 1.  The role of corticotropin-releasing factor in drug addiction.

Authors:  Z Sarnyai; Y Shaham; S C Heinrichs
Journal:  Pharmacol Rev       Date:  2001-06       Impact factor: 25.468

2.  V1b and CRHR1 receptor heterodimerization mediates synergistic biological actions of vasopressin and CRH.

Authors:  Brigitte Murat; Dominic Devost; Miriam Andrés; Julie Mion; Véra Boulay; Maithé Corbani; Hans H Zingg; Gilles Guillon
Journal:  Mol Endocrinol       Date:  2012-02-02

3.  The pharmacology of the novel and selective sigma ligand, PD 144418.

Authors:  H C Akunne; S Z Whetzel; J N Wiley; A E Corbin; F W Ninteman; H Tecle; Y Pei; T A Pugsley; T G Heffner
Journal:  Neuropharmacology       Date:  1997-01       Impact factor: 5.250

4.  Extracellular concentrations of cocaine and dopamine are enhanced during chronic cocaine administration.

Authors:  H O Pettit; H T Pan; L H Parsons; J B Justice
Journal:  J Neurochem       Date:  1990-09       Impact factor: 5.372

5.  The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity.

Authors:  L de Lecea; T S Kilduff; C Peyron; X Gao; P E Foye; P E Danielson; C Fukuhara; E L Battenberg; V T Gautvik; F S Bartlett; W N Frankel; A N van den Pol; F E Bloom; K M Gautvik; J G Sutcliffe
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

6.  Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior.

Authors:  T Sakurai; A Amemiya; M Ishii; I Matsuzaki; R M Chemelli; H Tanaka; S C Williams; J A Richardson; G P Kozlowski; S Wilson; J R Arch; R E Buckingham; A C Haynes; S A Carr; R S Annan; D E McNulty; W S Liu; J A Terrett; N A Elshourbagy; D J Bergsma; M Yanagisawa
Journal:  Cell       Date:  1998-02-20       Impact factor: 41.582

7.  Dopamine-dependent responses to cocaine depend on corticotropin-releasing factor receptor subtypes.

Authors:  Lin Lu; Zhiyuan Liu; Mingsheng Huang; Zhangying Zhang
Journal:  J Neurochem       Date:  2003-03       Impact factor: 5.372

8.  Dynamic interaction between sigma-1 receptor and Kv1.2 shapes neuronal and behavioral responses to cocaine.

Authors:  Saïd Kourrich; Teruo Hayashi; Jian-Ying Chuang; Shang-Yi Tsai; Tsung-Ping Su; Antonello Bonci
Journal:  Cell       Date:  2013-01-17       Impact factor: 41.582

9.  Corticotropin-releasing factor requires CRF binding protein to potentiate NMDA receptors via CRF receptor 2 in dopamine neurons.

Authors:  Mark A Ungless; Vineeta Singh; Tara L Crowder; Rami Yaka; Dorit Ron; Antonello Bonci
Journal:  Neuron       Date:  2003-07-31       Impact factor: 17.173

10.  Cocaine inhibits dopamine D2 receptor signaling via sigma-1-D2 receptor heteromers.

Authors:  Gemma Navarro; Estefania Moreno; Jordi Bonaventura; Marc Brugarolas; Daniel Farré; David Aguinaga; Josefa Mallol; Antoni Cortés; Vicent Casadó; Carmen Lluís; Sergi Ferre; Rafael Franco; Enric Canela; Peter J McCormick
Journal:  PLoS One       Date:  2013-04-18       Impact factor: 3.240
View more
  28 in total

1.  Orexin A/Hypocretin Modulates Leptin Receptor-Mediated Signaling by Allosteric Modulations Mediated by the Ghrelin GHS-R1A Receptor in Hypothalamic Neurons.

Authors:  Mireia Medrano; David Aguinaga; Irene Reyes-Resina; Enric I Canela; Josefa Mallol; Gemma Navarro; Rafael Franco
Journal:  Mol Neurobiol       Date:  2017-07-17       Impact factor: 5.590

2.  Opioid-galanin receptor heteromers mediate the dopaminergic effects of opioids.

Authors:  Ning-Sheng Cai; César Quiroz; Jordi Bonaventura; Alessandro Bonifazi; Thomas O Cole; Julia Purks; Amy S Billing; Ebonie Massey; Michael Wagner; Eric D Wish; Xavier Guitart; William Rea; Sherry Lam; Estefanía Moreno; Verònica Casadó-Anguera; Aaron D Greenblatt; Arthur E Jacobson; Kenner C Rice; Vicent Casadó; Amy H Newman; John W Winkelman; Michael Michaelides; Eric Weintraub; Nora D Volkow; Annabelle M Belcher; Sergi Ferré
Journal:  J Clin Invest       Date:  2019-03-26       Impact factor: 14.808

3.  Nicotinic receptor blockade decreases fos immunoreactivity within orexin/hypocretin-expressing neurons of nicotine-exposed rats.

Authors:  Steven J Simmons; Taylor A Gentile; Lili Mo; Fionya H Tran; Sisi Ma; John W Muschamp
Journal:  Behav Brain Res       Date:  2016-08-01       Impact factor: 3.332

4.  Functional μ-Opioid-Galanin Receptor Heteromers in the Ventral Tegmental Area.

Authors:  Estefanía Moreno; César Quiroz; William Rea; Ning-Sheng Cai; Josefa Mallol; Antoni Cortés; Carme Lluís; Enric I Canela; Vicent Casadó; Sergi Ferré
Journal:  J Neurosci       Date:  2016-12-22       Impact factor: 6.167

Review 5.  Arrestin recruitment and signaling by G protein-coupled receptor heteromers.

Authors:  Kendall L Mores; Robert J Cassell; Richard M van Rijn
Journal:  Neuropharmacology       Date:  2018-11-09       Impact factor: 5.250

Review 6.  Allosteric mechanisms within the adenosine A2A-dopamine D2 receptor heterotetramer.

Authors:  Sergi Ferré; Jordi Bonaventura; Dardo Tomasi; Gemma Navarro; Estefanía Moreno; Antonio Cortés; Carme Lluís; Vicent Casadó; Nora D Volkow
Journal:  Neuropharmacology       Date:  2015-06-04       Impact factor: 5.250

7.  Orexin receptors in GtoPdb v.2021.3.

Authors:  Paul Coleman; Luis de Lecea; Anthony Gotter; Jim Hagan; Daniel Hoyer; Thomas Kilduff; Jyrki P Kukkonen; Rod Porter; John Renger; Jerome M Siegel; Gregor Sutcliffe; Neil Upton; Christopher J Winrow
Journal:  IUPHAR BPS Guide Pharm CITE       Date:  2021-09-02

Review 8.  Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders.

Authors:  Ying Han; Kai Yuan; Yongbo Zheng; Lin Lu
Journal:  Neurosci Bull       Date:  2019-11-28       Impact factor: 5.203

Review 9.  Orexin Signaling: A Complex, Multifaceted Process.

Authors:  Natasha C Dale; Daniel Hoyer; Laura H Jacobson; Kevin D G Pfleger; Elizabeth K M Johnstone
Journal:  Front Cell Neurosci       Date:  2022-04-13       Impact factor: 6.147

Review 10.  Basic Pharmacological and Structural Evidence for Class A G-Protein-Coupled Receptor Heteromerization.

Authors:  Rafael Franco; Eva Martínez-Pinilla; José L Lanciego; Gemma Navarro
Journal:  Front Pharmacol       Date:  2016-03-31       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.